[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Intellia Thera CS (NTLA)

Intellia Thera CS (NTLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,910,000
  • Shares Outstanding, K 139,722
  • Annual Sales, $ 67,670 K
  • Annual Income, $ -412,690 K
  • EBIT $ -441 M
  • EBITDA $ -425 M
  • 60-Month Beta 1.93
  • Price/Sales 27.03
  • Price/Cash Flow N/A
  • Price/Book 2.54

Options Overview Details

View History
  • Implied Volatility 90.59% (+8.54%)
  • Historical Volatility 81.25%
  • IV Percentile 57%
  • IV Rank 23.49%
  • IV High 154.61% on 10/27/25
  • IV Low 70.94% on 08/20/25
  • Expected Move (DTE 30) 2.34 (18.42%)
  • Put/Call Vol Ratio 0.43
  • Today's Volume 8,032
  • Volume Avg (30-Day) 5,781
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 88,544
  • Open Int (30-Day) 96,898
  • Expected Range 10.35 to 15.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.81
  • Number of Estimates 8
  • High Estimate $-0.68
  • Low Estimate $-0.94
  • Prior Year $-0.99
  • Growth Rate Est. (year over year) +18.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.76 +7.95%
on 04/29/26
16.97 -25.22%
on 04/23/26
-2.26 (-15.12%)
since 04/17/26
3-Month
11.62 +9.21%
on 03/30/26
16.97 -25.22%
on 04/23/26
+0.21 (+1.68%)
since 02/18/26
52-Week
6.83 +85.80%
on 05/30/25
28.25 -55.08%
on 10/20/25
+4.19 (+49.29%)
since 05/16/25

Most Recent Stories

More News
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

Presented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027 Recently resumed patient screening in MAGNITUDE...

NTLA : 12.69 (-7.17%)
Intellia Therapeutics Stock Is Down Nearly 95% From Its Record Highs but Cathie Wood Keeps Buying

Despite Intellia's severe stock drop from its 2021 peak, Cathie Wood is buying big.

ARKG : 28.11 (-0.14%)
REGN : 629.68 (-9.82%)
NTLA : 12.69 (-7.17%)
ARKK : 74.51 (-0.52%)
Intellia Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 12.69 (-7.17%)
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 12.69 (-7.17%)
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 12.69 (-7.17%)
Intellia Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 12.69 (-7.17%)
Intellia Therapeutics Pops on CRISPR Trial Success. Does That Make NTLA Stock a Buy?

Intellia Therapeutics stock soars on promising Phase 3 results for its hereditary angioedema (HAE) candidate. But is there any further upside left in NTLA shares?

REGN : 629.68 (-9.82%)
NTLA : 12.69 (-7.17%)
3 Biotech Stocks That Could Benefit from the Patent Cliff

Biotech M&A is surging ahead of a $300B patent cliff. Here are 3 gene-editing stocks investors are watching as potential acquisition targets

BEAM : 26.81 (-4.01%)
CRSP : 48.56 (+0.31%)
MRK : 112.56 (+1.06%)
BMY : 57.31 (+0.54%)
NTLA : 12.69 (-7.17%)
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema

CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 12.69 (-7.17%)
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints;  favorable safety and tolerability data observed Single dose of lonvo-z freed most patients from...

NTLA : 12.69 (-7.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the...

See More

Key Turning Points

3rd Resistance Point 15.45
2nd Resistance Point 14.66
1st Resistance Point 13.68
Last Price 12.69
1st Support Level 11.91
2nd Support Level 11.12
3rd Support Level 10.14

See More

52-Week High 28.25
Fibonacci 61.8% 20.07
Fibonacci 50% 17.54
Fibonacci 38.2% 15.01
Last Price 12.69
52-Week Low 6.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.